Volume 5.42 | Nov 7

Prostate Cell News 5.42 November 7, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
 
TOP STORY
Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
Researchers report the development of a potent binding function 3 (BF3) inhibitor, 3-(2,3-dihydro-1H-indol-2-yl)-1H-indole, which demonstrates excellent antiandrogen potency and anti-PSA activity and abrogates the androgen-induced proliferation of androgen-sensitive and enzalutamide-resistant PCa cell lines. [Chem Biol]
Abstract | Graphical Abstract
[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Androgen Receptor Interacting Protein HSPBAP1 Facilitates Growth of Prostate Cancer Cells in Androgen-Deficient Conditions
Investigators performed an RNAi screen on 2068 genes, including kinases, phosphatases, epigenetic enzymes and other druggable gene targets. High-content cell spot microarray screen was performed in VCaP cells in the presence and absence of androgens with detection of Ki67 and cleaved ADP-ribose polymerase as assays for cell proliferation and apoptosis. [Int J Cancer] Abstract

Sortilin Regulates Progranulin Action in Castration-Resistant Prostate Cancer Cells
Scientists show that sortilin is expressed at very low levels in castration-resistant PC3 and DU145 cells. Significantly, enhancing sortilin expression in PC3 and DU145 cells severely diminishes progranulin levels, and inhibits motility, invasion, proliferation and anchorage-independent growth. [Endocrinology]
Abstract | Full Article

Complex Impacts of PI3K/AKT Inhibitors to Androgen Receptor Gene Expression in Prostate Cancer Cells
Four human prostate cancer cell lines with different genetic backgrounds were treated with five PI3K/AKT inhibitors and or AKT siRNA. PI3K/AKT inhibitors had various impacts on androgen receptor (AR) protein expressions primarily through alterations of AR gene transcription initiation and RNA splicing. [PLoS One]
Full Article

TNFα-Mediated Loss of β-Catenin/E-Cadherin Association and Subsequent Increase in Cell Migration Is Partially Restored by NKX3.1 Expression in Prostate Cells
Altered β-catenin signaling upon TNFα exposure, and relation to loss of function of the tumor suppressor NKX3.1 was examined in prostate cancer cells. Researchers used an in vitro prostate inflammation model to demonstrate altered sub-cellular localization of β-catenin following increased phosphorylation of Akt(S473) and GSK3β(S9). [PLoS One] Full Article

RNA-Seq Profiling of a Radiation Resistant and Radiation Sensitive Prostate Cancer Cell Line Highlights Opposing Regulation of DNA Repair and Targets for Radiosensitization
Using an in vitro model to screen for novel biomarkers of radioresistance, transcriptome analysis of a radioresistant and radiosensitive prostate cancer cell line was performed. [BMC Cancer] Abstract | Full Article

The Anti-Proliferative Effects of Enterolactone in Prostate Cancer Cells: Evidence for the Role of DNA Licencing Genes, mi-R106b Cluster Expression, and PTEN Dosage
Researchers investigated what concentration(s) of enterolactone can restrict proliferation in multiple stages of prostate cancer using an in vitro model system of prostate disease. [Nutrients] Full Article

Angiopoietin-Like Protein 2 Induces Androgen-Independent and Malignant Behavior in Human Prostate Cancer Cells
Androgen-dependent LNCaP and androgen-independent LNCaP/AI cells, respectively, were cultured in fetal bovine and charcoal-stripped medium. Cell proliferation, androgen dependence, migration and invasion, respectively, were examined under the overexpression and knockdown of angiopoietin-like protein 2 (ANGPTL2) by transfection of ANGPTL2 cDNA and its small-interfering RNA. [Oncol Rep] Abstract

CLINICAL RESEARCH

Chromosomal Instability in Cell-Free DNA Is a Serum Biomarker for Prostate Cancer
DNA was extracted from serum of 204 patients with prostate cancer, 207 male controls, and patients with benign hyperplasia and prostatitis. DNA was amplified by use of random primers, tagged with molecular identifiers, sequenced on a SOLID system, and aligned to the human genome. [Clin Chem] Abstract

A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer
Preclinical studies demonstrated that non-nucleoside reverse transcriptase inhibitors used for the treatment of HIV could antagonize tumor development. This led the authors to assess the efficacy of efavirenz in patients with metastatic castration-resistant prostate cancer in a multicenter Phase II study. [Oncologist]
Abstract | Full Article

Listen Now: Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
Models of Neuroendocrine Prostate Cancer
The authors review the relevant xenograft tumor and genetically engineered mouse models of neuroendocrine prostate cancer, with the aim of addressing salient features and clinical relevance. [Endocr Relat Cancer] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
Tokai Pharmaceuticals Announces Interim Phase II Data on Galeterone in Patients with Advanced Prostate Cancer
Tokai Pharmaceuticals, Inc. announced that updated, interim results from the company’s ongoing Phase II clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer will be presented. [Press release from Tokai Pharmaceuticals, Inc. discussing research to be presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics, Barcelona]
Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your Free Copy.
 
INDUSTRY NEWS
Prostate Cancer Foundation Announces Movember Foundation-PCF Scientific Reproducibility Initiative
The Prostate Cancer Foundation (PCF), with funding from the Movember Foundation, announced an innovative program called the Movember Foundation-PCF Scientific Reproducibility Initiative. Due to reports of issues related to the reproducibility of high-impact biomedical research findings, this initiative will assess the reproducibility of research findings with implications for prostate cancer patients. [The Prostate Cancer Foundation] Press Release

City of Hope Awarded $8 Million to Launch Stem Cell Therapy Clinic Focused on Fighting Incurable Disease
Identifying cures for currently incurable diseases and providing patients safe, fast, and potentially life-saving treatments is the focus of City of Hope’s new Alpha Clinic for Cell Therapy and Innovation. The clinic is funded by an $8 million, 5-year grant from the California Institute for Regenerative Medicine. [City of Hope]
Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Cell & Gene Therapy Forum 2015
January 26-28, 2015
Washington DC, United States

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Prostate Cancer and Prostatic Diseases (Louisiana State University)

NEW Postdoctoral Associate – Biomarkers Associated with Prostate Cancer (Duke Molecular Physiology Institute)

NEW Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Fellow – Metabolomics and Prostate Cancer (University of Maryland)

Senior Research Associate – Nanomedicine (University of East Anglia)

Postdoctoral Fellow – Role of Deregulated PTEN/FOXO1 Pathway in Prostate Cancer (Mayo Clinic)

Postdoctoral Fellow – Oncology (Johnson & Johnson Pharmaceutical Research & Development)

Postdoctoral Fellow – Prognostic Biomarkers for Prostate Cancer (McGill University)

Physician Scientist – Prostate Cancer Genomics (University of Chicago)

Tenure Track Position – Cancer Biology (Wake Forest Baptist Medical Center)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us